Evidence map›Paper›PMID 40076808›Full record

ArticleInternational journal of molecular sciences2025

Rita Russo, Antonio Colantuono, Sonia Di Gaetano, Domenica Capasso, Annalisa Tito, Emilia Pedone, Luciano Pirone

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rita RussoInstitute of Biostructures and Bioimaging, Via Pietro Castellino 111, 80131 Naples, Italy.ORCID 0000-0002-7960-4864
Antonio ColantuonoArterra Bioscience S.p.A., Via Benedetto Brin 69, 80142 Napoli, Italy.ORCID 0000-0003-3527-838X
Sonia Di GaetanoInstitute of Biostructures and Bioimaging, Via Pietro Castellino 111, 80131 Naples, Italy.ORCID 0000-0001-5523-3619
Domenica CapassoDepartment of Physics "Ettore Pancini", University of Naples Federico II, Via Cinthia 4, 80126 Naples, Italy.ORCID 0000-0001-7201-3431
Annalisa TitoArterra Bioscience S.p.A., Via Benedetto Brin 69, 80142 Napoli, Italy.
Emilia PedoneInstitute of Biostructures and Bioimaging, Via Pietro Castellino 111, 80131 Naples, Italy.ORCID 0000-0003-0203-8611
Luciano PironeInstitute of Biostructures and Bioimaging, Via Pietro Castellino 111, 80131 Naples, Italy.ORCID 0000-0002-7014-4689

Funding

National Research Council FOE-2021 DBA.AD005.225
6 · The paper itself

Abstract

Human galectin-3 (Gal-3), a β-galactoside binding lectin through its Carbohydrate Recognition Domain (CRD), is implicated in a wide range of cellular functions and is involved in critical biological processes including pathogen recognition, immune response, inflammation and fibrosis. Recently, Gal-3 has gained increasing attention for its role in pathological conditions such as cancer, where it influences cancer growth and progression, inflammatory processes and oxidative stress, opening the search for potential inhibitors. In this context, several naturally derived molecules have attracted particular interest, some of them being used in clinical trials. Here, we used the seeds of the legume

Indexed as

PhaseolusPlant ExtractsSeedsAnti-Inflammatory AgentsAntioxidantsCell Line, TumorGalectin 3HumansNeoplasmsPolyphenolsAnti-Inflammatory AgentsAntioxidantsGalectin 3Plant ExtractsPolyphenolsGal-3galectingalectins inhibitorsPhaseolus coccineus seed

Identifiers

PMID40076808
PMCPMC11900370

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.